Home
CELZ
CELZ News

Latest Creative Medical Technology Holdings Inc. (CELZ) News on April 3, 2025

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

GlobeNewswire

14 days ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit

Simply Wall St.

18 days ago

Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

GlobeNewswire

a month ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

GlobeNewswire

a month ago

Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

GlobeNewswire

2 months ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

GlobeNewswire

2 months ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

GlobeNewswire

2 months ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

GlobeNewswire

2 months ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

GlobeNewswire

5 months ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.02 loss in 3Q 2023)

Simply Wall St.

5 months ago

Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.02 loss in 3Q 2023)

Creative Medical to sell 418,552 shares at $4.42 in registered direct offering

TipRanks

5 months ago

Creative Medical to sell 418,552 shares at $4.42 in registered direct offering

Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

5 months ago

Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

GlobeNewswire

8 months ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns

Simply Wall St.

9 months ago

Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns

Creative Medical Technology Holdings Provides Corporate Update

GlobeNewswire

9 months ago

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

GlobeNewswire

9 months ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Provides Corporate Update

Business Wire

a year ago

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Business Wire

a year ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Business Wire

a year ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Carver in New York rejects unsolicited takeover offer

American Banker

a year ago

Carver in New York rejects unsolicited takeover offer

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

GlobeNewswire

a year ago

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

GlobeNewswire

a year ago

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

GlobeNewswire

a year ago

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3

NewMediaWire

a year ago

Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

ACCESSWIRE

a year ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Business Wire

a year ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

HUB Cyber Security Seals New Agreement with Prominent International Entertainment Corporation

GlobeNewswire

a year ago

HUB Cyber Security Seals New Agreement with Prominent International Entertainment Corporation

Remark Holdings Adjourns Annual Shareholder Meeting Until December 29, 2023

PR Newswire

a year ago

Remark Holdings Adjourns Annual Shareholder Meeting Until December 29, 2023

Precision Optics Enters into Production and Technology Licensing Agreement for Single-Use Cystoscopy Robotic Surgery Program

PR Newswire

a year ago

Precision Optics Enters into Production and Technology Licensing Agreement for Single-Use Cystoscopy Robotic Surgery Program

Presto Names Kat Hoffman-Flynt Chief Operating Officer

GlobeNewswire

a year ago

Presto Names Kat Hoffman-Flynt Chief Operating Officer

3 Top-Rated Cannabis Stocks That Analysts Are Loving Now

InvestorPlace

a year ago

3 Top-Rated Cannabis Stocks That Analysts Are Loving Now

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

GlobeNewswire

a year ago

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

GlobeNewswire

a year ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Zenvia Inc. (NASDAQ:ZENV) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Zenvia Inc. (NASDAQ:ZENV) Q3 2023 Earnings Call Transcript

Mawson Infrastructure Group Inc. Announces Monthly Operational Update for October 2023

GlobeNewswire

a year ago

Mawson Infrastructure Group Inc. Announces Monthly Operational Update for October 2023

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

ACCESSWIRE

a year ago

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

Analysts Are Upgrading Mawson Infrastructure Group, Inc. (NASDAQ:MIGI) After Its Latest Results

Simply Wall St.

a year ago

Analysts Are Upgrading Mawson Infrastructure Group, Inc. (NASDAQ:MIGI) After Its Latest Results

Associated Press Finance

a year ago

Phoenix New Media: Q3 Earnings Snapshot

Creative Medical Technology Holdings Provides Corporate Update

PR Newswire

a year ago

Creative Medical Technology Holdings Provides Corporate Update

ACCESSWIRE

a year ago

CORRECTION BY SOURCE: Silversun Technologies Reports Third Quarter 2023 Results

ACCESSWIRE

a year ago

SilverSun Technologies Reports Third Quarter 2023 Results

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

GlobeNewswire

a year ago

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

Research Frontiers Incorporated (NASDAQ:REFR) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Research Frontiers Incorporated (NASDAQ:REFR) Q3 2023 Earnings Call Transcript

Share on Social Networks: